B&L merger approved

Article

Bausch & Lomb's shareholders have voted to approve a merger with Warburg Pincus.

Bausch & Lomb's shareholders have voted to approve a merger with Warburg Pincus.

In accordance with the terms of the merger, each outstanding share of common and Class B stock will be cancelled and converted into the right to receive $65 in cash, without interest, less any applicable withholding taxes.

The merger is expected to close early in the fourth quarter of this year.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.